Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:ZYME

Zymeworks Q3 2026 Earnings Date & Estimates

Zymeworks logo
$28.22 -0.22 (-0.77%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$27.44 -0.78 (-2.75%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zymeworks is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for November 5, 2026 at 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Zymeworks in Q3 2026

Zymeworks is expected to post earnings of $2.26 per share on revenue of $227.38 million. In the same quarter a year earlier Zymeworks reported -$0.26 per share on revenue of $27.61 million. Zymeworks last reported on August 7, 2026, posting -$0.62 per share and missing the -$0.5620 consensus estimate. Zymeworks has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$2.26
Expected Revenue
$227.38 million
Prior-Year EPS
-$0.26
Prior-Year Revenue
$27.61 million
Expected Revenue Growth
+723.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.62 (Missed by -$0.0580)
Last Quarter Revenue
$3.23 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Zymeworks Q3 2026 Earnings FAQ

Zymeworks (NASDAQ:ZYME) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Zymeworks' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Zymeworks to post earnings of $2.26 per share for Q3 2026.

The consensus revenue estimate for Zymeworks is $227.38 million for Q3 2026.

Zymeworks Earnings Headlines

Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026
October 24 at 7:20 AM  |  marketscreener.comM
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
October 24 at 2:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/24/3387658/0/en/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-antibody-drug-conjugate-zw191-at-esmo-congress-2026.html
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
 |  Porter & Company (Ad)
Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones
October 23 at 7:36 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/zymeworks-signs-roche-deal-55-104942113.html
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
October 23 at 10:10 AM  |  msn.comhttps://www.msn.com/en-gb/money/general/zymeworks-licenses-experimental-lung-cancer-drug-to-roche-in-up-to-813-million-deal/ar-AA2fU5eS
Zymeworks Inc. Enters Into An Exclusive Global License And Collaboration Agreement With F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc. For ZW209, A Trispecific T Cell ...
October 23 at 10:10 AM  |  marketscreener.comM
See More Zymeworks Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zymeworks? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zymeworks and other key companies, straight to your email.

About Zymeworks

Zymeworks (NASDAQ:ZYME) is a biopharmaceutical company focused on discovering, developing and commercializing multifunctional biotherapeutics for cancer and other serious diseases. The company is headquartered in Vancouver, British Columbia, and has historically operated internationally through research, development and collaboration activities.

Zymeworks’ technology platforms include Azymetric, which is designed to support the development of engineered antibody therapeutics, and ZymeLink, which enables the creation of antibody-drug conjugates and other targeted therapies. These platforms are intended to produce treatments that engage multiple biological targets or deliver therapeutic payloads selectively to diseased cells.

The company’s lead product is zanidatamab, a bispecific antibody targeting HER2. In 2024, the U.S. Food and Drug Administration approved zanidatamab, marketed as Ziihera, for previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. Zymeworks has developed zanidatamab through partnerships, including a commercialization agreement with Jazz Pharmaceuticals, which markets the therapy in the United States and other territories.

View Zymeworks Profile
Earnings Tools